GW Pharmaceuticals PLC- (GWPH) Receives Daily News Sentiment Rating of 0.08

Media headlines about GW Pharmaceuticals PLC- (NASDAQ:GWPH) have been trending somewhat positive on Wednesday, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GW Pharmaceuticals PLC- earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.5190765929276 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:

Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) opened at $131.32 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.59 and a quick ratio of 7.47. The stock has a market cap of $3,330.00, a P/E ratio of -18.60 and a beta of 2.65. GW Pharmaceuticals PLC- has a one year low of $92.65 and a one year high of $140.52.

A number of research analysts recently commented on GWPH shares. BidaskClub raised shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a research report on Friday, December 22nd. Goldman Sachs Group raised shares of GW Pharmaceuticals PLC- from a “neutral” rating to a “buy” rating and set a $174.00 price objective on the stock in a research report on Thursday, December 14th. Cantor Fitzgerald set a $208.00 price objective on shares of GW Pharmaceuticals PLC- and gave the company a “buy” rating in a research report on Monday, December 4th. Bank of America lowered their price objective on shares of GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating on the stock in a research report on Tuesday, November 14th. Finally, Zacks Investment Research raised shares of GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. GW Pharmaceuticals PLC- has a consensus rating of “Hold” and an average price target of $148.78.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2018/01/10/gw-pharmaceuticals-plc-gwph-receives-daily-news-sentiment-rating-of-0-08.html.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Insider Buying and Selling by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit